2011
DOI: 10.1038/nature10177
|View full text |Cite
|
Sign up to set email alerts
|

In vivo genome editing restores haemostasis in a mouse model of haemophilia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

6
404
0
1

Year Published

2011
2011
2017
2017

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 501 publications
(411 citation statements)
references
References 28 publications
(41 reference statements)
6
404
0
1
Order By: Relevance
“…ZFN-based gene therapy for HIV infection is currently under phase 2 clinical trials, yielding some successful cases (8). Other studies suggested that ZF-based gene control could also be therapeutically effective for hemophilia (9) and Parkinson's disease (10). For the success of these technologies, however, two issues, toxicity and low efficiency, should be resolved (4,5,11).…”
mentioning
confidence: 99%
“…ZFN-based gene therapy for HIV infection is currently under phase 2 clinical trials, yielding some successful cases (8). Other studies suggested that ZF-based gene control could also be therapeutically effective for hemophilia (9) and Parkinson's disease (10). For the success of these technologies, however, two issues, toxicity and low efficiency, should be resolved (4,5,11).…”
mentioning
confidence: 99%
“…Genome editing has become an important technique to study human disease in in vivo models 7 and may one day become an established therapeutic approach to correct disease-causing mutations 8 . Here we have utilized transcription activator-like effector nuclease (TALEN)-mediated genome editing to introduce the naturally occurring À 175T4C HPFH mutation into the g-globin promoter in erythroid cell lines.…”
mentioning
confidence: 99%
“…66 Another option is to integrate the wild-type copy of the gene into the endogenous locus, allowing for endogenous gene regulation, which is expected to be more physiological. 67 While the majority of liver diseases are caused by loss of function genetic mutations, there are other liver diseases that are initiated by aberrant or excessive activity of a gene. For example, familial hypercholesterolemia can be caused by nonsense mutations in PCSK9 gene.…”
Section: Key Pointmentioning
confidence: 99%